pharmaceutical-investing Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm
pharmaceutical-investing Aquestive Therapeutics Announces Regulatory Development for Anaphylm Sublingual Film and Provides Business Update
pharmaceutical-investing Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
pharmaceutical-investing Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
pharmaceutical-investing Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
pharmaceutical-investing Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
pharmaceutical-investing Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm
pharmaceutical-investing IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil
LAURION Reports Wide Mineralized Zones and High-Grade Polymetallic Intercepts from LBX25-097 and LBX25-100, Advancing Structural Continuity at Ishkoday
